Sol-Gel Technologies

SLGLPhase 3

Sol-Gel Technologies leverages its patented silica-based microencapsulation technology to create novel topical dermatological products with improved efficacy, stability, and patient tolerability. The company transitioned to a commercial-stage entity with the U.S. launch of TWYNEO® in 2022 and is advancing a pipeline targeting acne, rosacea, and other dermatological conditions. Its strategy combines proprietary development with strategic partnerships, such as the license agreement with Galderma for Epsolay® and TWYNEO®, to maximize the reach of its innovative treatments.

Market Cap

$203.3M

Employees

50-100

Focus

Biotech

SLGL · Stock Price

USD 72.970.38 (-0.52%)

Historical price data

AI Company Overview

Technology Platform

Proprietary silica-based microencapsulation (Sol-Gel) technology for the controlled release and stabilization of active ingredients in topical dermatological formulations.

Pipeline Snapshot

15 drugs in pipeline, 9 in Phase 3

Drug	Indication	Stage
Patidegib Topical Gel + Patidegib Topical Gel with no active patidegib	Gorlin Syndrome	Phase 3
Patidegib Topical Gel, 2%	Basal Cell Nevus Syndrome	Phase 3
S6G5T-3 + S6G5T-8	Acne Vulgaris	Phase 3
S6G5T-3 + S6G5T-8	Acne Vulgaris	Phase 3
5-FU Cream + Efudex® + Vehicle	Actinic Keratosis (AK)	Phase 3

Funding History

Total raised: $25M

PIPE$25MPerceptive AdvisorsFeb 15, 2021

IPOUndisclosedUndisclosedJan 15, 2019

Opportunities

Significant growth opportunity lies in capturing market share for TWYNEO® in the large U.S.

acne market and expanding the technology platform into new dermatological indications, such as rare diseases like Epidermolysis Bullosa Simplex, which offer orphan drug incentives and high unmet need.

Risk Factors

Key risks include commercial execution challenges in a crowded acne market, dependence on partner Galderma for ex-U.S.

revenue, potential need for additional financing, and the inherent risks of clinical development for pipeline candidates.

Competitive Landscape

Competes with large dermatology companies (e.g., Galderma, Ortho Dermatologics) and other topical therapy developers. Primary differentiation is its proprietary Sol-Gel microencapsulation technology, which enables novel, stabilized formulations with improved tolerability profiles that are difficult for competitors to replicate.